Alprolix Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Alprolix is a recombinant coagulation factor IX Fc fusion protein used to treat and prevent bleeding episodes in individuals with hemophilia B. It works by replacing the missing factor IX to support normal blood clotting and features an extended half-life, which helps reduce the frequency of infusions needed for effective disease management.

The main products in the Alprolix market include recombinant coagulation factor IX and plasma-derived coagulation factor IX. Recombinant coagulation factor IX is a bioengineered protein designed to replace deficient or defective factor IX in patients with hemophilia B, enabling proper clot formation and reducing excessive bleeding. The available formulations include injectable solutions and powders for reconstitution. These products are used in applications such as hemophilia B treatment, prophylaxis, and surgical management and are distributed through hospitals, specialty clinics, and online pharmacies.

Tariffs have moderately impacted the alprolix market by increasing costs associated with imported recombinant protein manufacturing inputs and specialized cold chain logistics. These effects are most visible in hospital and specialty clinic distribution channels across north america and europe. Higher tariffs have placed pressure on treatment pricing and reimbursement negotiations for hemophilia therapies. At the same time, tariffs are encouraging regional biologics manufacturing and local supply chain development. This supports long term availability of advanced coagulation therapies.

The alprolix market research report is one of a series of new reports from The Business Research Company that provides alprolix market statistics, including alprolix industry global market size, regional shares, competitors with a alprolix market share, detailed alprolix market segments, market trends and opportunities, and any further data you may need to thrive in the alprolix industry. This alprolix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alprolix market size has grown strongly in recent years. It will grow from $1.32 million in 2025 to $1.45 million in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to high unmet need in hemophilia b management, limitations of plasma derived therapies, proven efficacy of recombinant factor ix, increasing diagnosis of inherited bleeding disorders, early adoption of prophylactic treatment protocols.

The alprolix market size is expected to see strong growth in the next few years. It will grow to $2.09 million in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising hemophilia b patient population, increasing demand for long acting clotting factors, improved access to specialty hemophilia care, expansion of home based infusion programs, continued innovation in factor fusion technologies. Major trends in the forecast period include growing adoption of extended half life factor ix therapies, increasing shift toward prophylactic hemophilia management, rising preference for reduced infusion frequency treatments, expansion of recombinant coagulation factor usage, improved patient adherence through long acting therapies.

The rising prevalence of hemophilia B is expected to drive the growth of the Alprolix market in the coming years. Hemophilia B, also known as Christmas disease, is a rare inherited bleeding disorder resulting from a deficiency or absence of clotting factor IX. The growing prevalence of hemophilia B is largely attributed to improved diagnostic methods, increased awareness and reporting, advancements in healthcare systems that enable earlier detection, and longer life expectancy among patients due to improved treatment options. Alprolix, a long-acting recombinant clotting factor IX, supports the management of hemophilia B by reducing bleeding episodes and decreasing the frequency of infusions through its extended half-life, thereby enhancing patients' quality of life. For instance, in October 2025, according to a report published by the World Federation of Hemophilia (WFH), as of 2024 there were 271,918 identified patients with hemophilia worldwide, including 224,353 individuals with hemophilia A and 45,600 with hemophilia B. Therefore, the increasing prevalence of hemophilia B is driving the Alprolix market.

The Alprolix market has experienced notable advancements in recent years, supported by a growing emphasis on innovative therapies to address unmet needs in hemophilia B treatment. Factor IX gene therapies work by delivering a functional copy of the FIX gene using adeno-associated virus (AAV) vectors, enabling long-term production of clotting factor IX, reducing bleeding episodes, and potentially providing a one-time treatment option for hemophilia B. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical manufacturing company, received U.S. FDA approval for Beqvez(TM) (fidanacogene elaparvovec), a gene therapy developed to treat hemophilia B. This approval represents a major milestone in hemophilia care, offering the possibility of a single-treatment solution that may significantly reduce or eliminate the need for regular clotting factor infusions. The therapy delivers a functional copy of the recombinant factor IX gene, resulting in sustained factor IX levels and improved bleeding control, supported by clinical trial data demonstrating durable efficacy and a favorable safety profile in patients with severe or moderately severe hemophilia B.

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired Emergent BioSolutions for an undisclosed amount. Through this acquisition, Bora Pharmaceuticals aims to strengthen its presence in the biotechnology and pharmaceutical sectors by expanding its contract development and manufacturing organization (CDMO) capabilities. Emergent BioSolutions Inc. is a US-based company that provides recombinant coagulation factor IX-based therapies.

Major companies operating in the alprolix market are Sanofi

North America was the largest region in the alprolix market in 2025. The regions covered in the alprolix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alprolix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The alprolix market consists of sales of alprolix 250IU and alprolix 500 IU. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alprolix Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses alprolix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alprolix ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The alprolix market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Recombinant Coagulation Factor IX; Plasma-Derived Coagulation Factor IX
• 2) By Formulation: Injectable Solution; Powder For Reconstitution
• 3) By Application: Hemophilia B Treatment; Prophylaxis; Surgery
• 4) By Distribution: Hospitals; Specialty Clinics; Online Pharmacies
• Companies Mentioned: Sanofi
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.